Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sampling plan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Sampling plan. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-002973-13 Sponsor Protocol Number: LOCAL/2013/JYL-01 Start Date*: 2015-02-25
    Sponsor Name:CHU de NIMES
    Full Title: Sampling Antibiotics in Renal Replacement Therapy: the AZUREA contribution
    Medical condition: The study population concerns patients in participating Intensive care unit simultaneously requiring Renal Replacement Therapy and intravenous antibiotic therapy (Piperacillin-Tazobactam, Meropenem...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014493-18 Sponsor Protocol Number: B1971012(6108A1-2003-EU) Start Date*: 2010-07-20
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in...
    Medical condition: Healthy volunteers (prevention of bacterial meningitis).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) PL (Completed) DE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000284-24 Sponsor Protocol Number: B5381012 Start Date*: 2020-02-03
    Sponsor Name:Pfizer Inc
    Full Title: A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA® IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS.
    Medical condition: Moderately to severely active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004264-19 Sponsor Protocol Number: NEODEX2 Start Date*: 2017-04-05
    Sponsor Name:Uppsala County Council
    Full Title: Anesthesia with dexmedetomidine and fentanyl for neonatal surgery. A pilot study.
    Medical condition: The state of anesthesia intraoperatively and pain postoperatively
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003259-39 Sponsor Protocol Number: NeuroClin02 Start Date*: 2014-03-28
    Sponsor Name:Neurochlore
    Full Title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.
    Medical condition: Diseases and Related Health Problems, tenth revision (ICD-10) and with a Childhood Autism Rating Scale (CARS) score > 34.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003303-31 Sponsor Protocol Number: BAY59-7939/13238 Start Date*: 2009-01-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer.
    Medical condition: Patients with acute, proximal DVT or acute PE who concomitantly use a strong CYP 3A4 inducer for the entire 3-month study duration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003394-15 Sponsor Protocol Number: VP-VEC-162-4201 Start Date*: 2016-06-28
    Sponsor Name:Vanda Pharmaceuitcals Inc.
    Full Title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
    Medical condition: This study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blin...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004632-11 Sponsor Protocol Number: D081RC00001 Start Date*: 2018-12-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olapa...
    Medical condition: Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016186 Fallopian tube cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016187 Fallopian tube cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004777-10 Sponsor Protocol Number: 107240 Start Date*: 2007-03-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without standard adjuvant chemo(-radio)therapy, to patients...
    Medical condition: Adult patients with pathologically proven MAGE A3-positive Non-Small Cell Lung Cancer in stage IB, II or III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009429-26 Sponsor Protocol Number: local 997 (P06034) Start Date*: 2010-03-15
    Sponsor Name:FREE UNIVERSITY OF BRUSSELS
    Full Title: A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS
    Medical condition: Compare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015174-35 Sponsor Protocol Number: 113629 Start Date*: 2009-11-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted pandemic H1N1 influenza candidate vaccine following a 0-28 day or 0-4 month vaccination schedule...
    Medical condition: Immunisation against A/California/7/2009 (H1N1)v-like influenza in male and female children aged 8 to 12 weeks.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000361-22 Sponsor Protocol Number: H9X-MC-GBGC Start Date*: 2017-05-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001227-13 Sponsor Protocol Number: SOPAZITHRO Start Date*: 2022-02-22
    Sponsor Name:Centre hospitalier intercommunal de Créteil
    Full Title: Evaluation of the Efficacy of 3-month Continuous Extended Treatment With Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults: a Multicentre Randomised Controlled Trial
    Medical condition: Patients with Purulent Oedematous Sinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10060841 Sinusitis bacterial PT
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004054-24 Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK Start Date*: 2019-03-18
    Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy
    Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000394-96 Sponsor Protocol Number: NEOGAP-CRC-01 Start Date*: 2023-01-31
    Sponsor Name:NEOGAP Therapeutics AB
    Full Title: A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer
    Medical condition: Stage IV colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002800-16 Sponsor Protocol Number: C3591024 Start Date*: 2019-12-10
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANT...
    Medical condition: Infections with suspected or confirmed Gram-negative pathogens
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10032531 Other specified bacterial infections in conditions classified elsewhere and of unspecified site LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) EE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006207-36 Sponsor Protocol Number: 19122011 Start Date*: 2012-09-27
    Sponsor Name:Proreo Pharma Innovation AG
    Full Title: A multi centre, double blind, randomised, placebo controlled crossover study to evaluate the efficacy and tolerability of picotamide in the prophylaxis of migraine in patients presenting with migra...
    Medical condition: Migraine with aura, ICD-10NA G43.1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-004530-14 Sponsor Protocol Number: 1199-0337 Start Date*: 2019-10-15
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nin...
    Medical condition: Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) FI (Completed) NO (Completed) DK (Completed) FR (Completed) CZ (Completed) PL (Completed) GR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002619-89 Sponsor Protocol Number: B1761031 Start Date*: 2019-06-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR...
    Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 12:59:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA